There also seems to be no difference in the syAE incidence among different anti-VEGF agents, as a study comparing the onset of syAE between patients treated with bevacizumab, ranibizumab, and aflibercept found no differences in the incidence of myocardial infarction, acute cerebrovascular disease, major bleeding, or hospitalization rates in 87,844 patients over an 11-year period [82]. Here, VEGFA is linked to myocardial infarction.